Skip to main content

Table 1 Comparison of baseline characteristics across patients with low (< 20 mg/L) vs. high (≥ 20 mg/L) CZP serum level

From: Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Axial spondyloarthritisAllCZP low (< 20 mg/L)CZP high (≥ 20 mg/L)P value
(n = 116)(n = 26)(n = 90)
 Age, years, mean (SD)42 (12)43 (11)41 (12)0.61
 Female, n (%)54 (47)14 (54)40 (44)0.40
 Disease duration, years, median (IQR)*2.6 (0.6–14.1)3.6 (1.7–11.7)2.3 (0.3–14.8)0.39
 ASDAS-CRP, mean (SD)2.6 (1.0)2.4 (0.9)2.7 (1.0)0.28
 HLA-B27 positive, n (%)87 (75)17 (65)70 (81)0.09
 Prior use of biologic DMARD, n (%)39 (34)10 (40)29 (33)0.54
 Concomitant conventional synthetic DMARD, n (%)22 (19)2 (8)20 (22)0.10
Rheumatoid arthritisAllCZP low (< 20 mg/L)CZP high (≥ 20 mg/L)P value
(n = 91)(n = 23)(n = 68)
 Age, years, mean (SD)54 (14)54 (16)54 (14)0.90
 Female, n (%)72 (79)13 (57)59 (87)< 0.05
 Disease duration, years, median (IQR)**10.1 (2.1–18.9)17.4 (6.8–23.5)7.4 (2.0–14.9)0.10
 DAS28, mean (SD)4.0 (1.4)3.5 (1.1)4.2 (1.5)0.08
 RF-positive, n (%)55 (61)12 (52)43 (66)0.23
 Anti-CCP positive, n (%)59 (66)13 (57)46 (71)0.21
 Prior use of biologic DMARD, n (%)44 (48)14 (64)30 (45)0.13
 Concomitant conventional synthetic DMARD, n (%)67 (74)16 (70)51 (75)0.53
Psoriatic arthritisAllCZP low (< 20 mg/L)CZP high (≥ 20 mg/L)P value
(n = 61)(n = 17)(n = 44)
 Age, years, mean (SD)50 (11)48 (12)51 (11)0.45
 Female, n (%)40 (66)12 (71)28 (64)0.61
 Disease duration, years, median (IQR)***6.6 (1.5–13.2)5.4 (1.3–13.5)6.9 (1.6–13.2)0.76
 DAS28, mean (SD)3.9 (1.3)3.9 (1.8)3.9 (1.2)0.99
 Prior use of biologic DMARD, n (%)30 (49)10 (59)20 (47)0.39
 Concomitant conventional synthetic DMARD, n (%)38 (67)8 (53)30 (71)0.20
  1. Data available in n = *68, **68, ***40 patients
  2. CZP certolizumab pegol, ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-C-reactive protein, DAS28 28-joint Disease Activity Score, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptides, DMARD disease-modifying antirheumatic drug, SD standard deviation, IQR interquartile range